Five Alzheimer’s Patients Back Anti-Amyloid Drugs, Urge Earlier Testing and Access
Updated
Updated · Fox News · Jul 15
Five Alzheimer’s Patients Back Anti-Amyloid Drugs, Urge Earlier Testing and Access
3 articles · Updated · Fox News · Jul 15
Summary
Five U.S. Alzheimer’s patients said new anti-amyloid treatments slowed their decline and helped preserve independence, arguing that early diagnosis gave them a chance to act before irreversible cognitive loss.
Those patients said the drugs are not cures but can add meaningful time when started early, even for people who had already followed exercise, diet and social-engagement guidance meant to reduce cognitive risk.
Individual accounts ranged from Ralph Carmona running five marathons after a 2015 diagnosis to Michael B., now 85, resuming independent driving, gym visits and daily exercise after treatment.
The group called for wider access to blood tests, faster recognition by primary-care doctors, stronger caregiver support and fewer Medicare and private-insurance barriers for eligible patients.
Their appeal reflects a broader push to make early detection a national priority as anti-amyloid therapies emerge as one of the first tools shown to slow Alzheimer’s progression.
A major review found new Alzheimer's drugs lack benefits. Why do patients report life-changing results?
A simple blood test can now diagnose Alzheimer's. Is our healthcare system prepared for the consequences?
Early Alzheimer's detection is a gift. But what is the 'incapacity trap' that could cost your family everything?
Alzheimer's Breakthroughs 2024: Efficacy, Access, and the Future of Diagnosis and Treatment
Overview
Alzheimer’s disease affects over 55 million people worldwide and is mainly caused by the buildup of amyloid plaques in the brain. These toxic protein clusters damage neurons, leading to the memory loss and cognitive decline seen in dementia. Normally, immune cells called microglia gather around these plaques, but in Alzheimer’s, they can’t clear them effectively. New anti-amyloid therapies aim to boost microglia’s ability to remove plaques, hoping to slow or stop disease progression. While these treatments offer hope, their real-world benefits, risks, and costs remain under discussion, highlighting the need for better diagnosis, access, and care strategies.